# Role of PRMT1 and PRMT5 in Breast Cancer

## TL;DR

This paper explores how PRMT1 and PRMT5 contribute to breast cancer development and progression, suggesting they could be important targets for new treatments.

## Contribution

The paper provides an updated overview of the roles of PRMT1 and PRMT5 in breast cancer signaling pathways.

## Key findings

- PRMT1 and PRMT5 regulate key signaling pathways in breast tumorigenesis.
- These enzymes are highlighted as potential therapeutic targets in breast cancer.
- Epigenetic modifications, including arginine methylation, are central to breast cancer progression.

## Abstract

Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage breast cancer is curable in ~70–80% of patients, while advanced metastatic breast cancer is considered incurable with current therapies. Breast cancer is a highly heterogeneous disease categorized into three main subtypes based on key markers orientating specific treatment strategies for each subtype. The complexity of breast carcinogenesis is often associated with epigenetic modification regulating different signaling pathways, involved in breast tumor initiation and progression, particularly by the methylation of arginine residues. Protein arginine methyltransferases (PRMT1-9) have emerged, through their ability to methylate histones and non-histone substrates, as essential regulators of cancers. Here, we present an updated overview of the mechanisms by which PRMT1 and PRMT5, two major members of the PRMT family, control important signaling pathways impacting breast tumorigenesis, highlighting them as putative therapeutic targets.